Acadia Appoints New Board Member, Dr. Patrice A. Harris
Acadia is pleased to announce that Patrice A. Harris, M.D., M.A., has joined its board of directors.
Category: Behavioral Health
Acadia CTCs Receive Highest Accreditation Scores from CARF International
Acadia’s network of Comprehensive Treatment Centers received accreditation from CARF International, one of the primary key regulators for opioid addiction treatment programs, with scores in the 99th percentile across 13 dimensions of performance. These scores demonstrate that the care provided in our programs exceeds the standards of quality opioid addiction treatment. For more information on … Read More
Acadia To Participate in Wells Fargo Healthcare Conference
Acadia is pleased to announce our participation in the 2023 Wells Fargo Healthcare Conference September 6-8.
Acadia Enters Joint Venture with SolutionHealth
Acadia Healthcare forms partnership with SolutionHealth to build a new 144-bed inpatient behavioral health hospital in southeastern New Hampshire.
Acadia Appoints New Chief Financial Officer
Acadia is pleased to announce that Heather Dixon has been named our new chief financial officer.
Acadia Names New Chief Human Resources Officer
Acadia welcomed Judith Scimone as our new chief human resources officer on May 15.
Acadia To Participate in BofA Securities Healthcare Conference
Acadia is pleased to announce our participation in the BofA Securities 2023 Healthcare Conference on May 9-11.
Bronson and Acadia name Deb Rozewicz as CEO of Bronson Behavioral Health Hospital
Acadia and Bronson are excited to welcome Deb Rozewicz as the new CEO of Bronson Behavioral Health Hospital.
Acadia Partners with Prestigious University and Health System in Pennsylvania
Acadia is pleased to announce that it has entered into a formal academic affiliation with Thomas Jefferson University’s Sidney Kimmel Medical College and Jefferson Health in Philadelphia, Pennsylvania.
Acadia Selected to Participate in Seelos Therapeutics Study
Acadia is honored to have been selected by Seelos Therapeutics to participate in a registration-directed study aimed at determining whether intranasal racemic ketamine can reduce symptoms of suicidal ideation in individuals who are suffering from depression.
